Both in Pharmaceuticals
Nuvation Bio vs Ocular Therapeutix
Over the past year NUVB returned −14.5% and OCUL returned −36.8%; their daily moves had a correlation of 0.22.
NUVB −14.5% OCUL −36.8%Growth of $1, one year, split-adjusted
| Metric | NUVB | OCUL |
|---|---|---|
| Price | $4.59 | $7.29 |
| Market cap | $1.61B | $1.60B |
| Today | +0.88% | +8.48% |
| 1 month | −18.3% | −7.4% |
| 6 months | +5.8% | −20.8% |
| Year to date | −48.8% | −40.0% |
| 1 year | −8.9% | −36.9% |
| Revenue growth (YoY) | +555.6% | +0.1% |
| Gross margin | 73.0% | 85.1% |
| Net margin | −198.3% | −584.5% |
| P/E (TTM) | — | — |
| Price / sales | 9.5× | 30.8× |
| Net cash | $399.4M | $525.8M |
| Dividend yield | — | — |
| Volatility (60d) | 53.0% | 75.9% |
| Short % of float | 23.9% | 15.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).